NCT01512108 - Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | Biotech Hunter

Enrollment

363

Participants

Timeline

Start Date

January 10, 2012

Primary Completion Date

April 26, 2013

Study Completion Date

April 26, 2013

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).

DRUG

oral anti-diabetic drug

An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.

Trial Locations (36)

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

103 0027

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

790 0067

Novo Nordisk Investigational Site, Ehime, Japan

812 0025

Novo Nordisk Investigational Site, Fukuoka

818 8502

Novo Nordisk Investigational Site, Fukuoka

820 8505

Novo Nordisk Investigational Site, Fukuoka

810 8798

Novo Nordisk Investigational Site, Fukuoka, Japan

815 8555

Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka

273 0121

Novo Nordisk Investigational Site, Kamagaya-shi, Chiba

582 0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

350 0851

Novo Nordisk Investigational Site, Kawagoe-shi, Saitama

800 0252

Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka

963 8851

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

862 0976

Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto

839 0863

Novo Nordisk Investigational Site, Kurume-shi, Fukuoka

880 0034

Novo Nordisk Investigational Site, Miyazaki

311 0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

950 1104

Novo Nordisk Investigational Site, Niigata-shi, Niigata

831 0016

Novo Nordisk Investigational Site, Okawa-shi, Fukuoka

532 0003

Novo Nordisk Investigational Site, Osaka-shi, Osaka

545 8586

Novo Nordisk Investigational Site, Osaka-shi, Osaka

144 0035

Novo Nordisk Investigational Site, Ota-ku, Tokyo

323 0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

870 8511

Novo Nordisk Investigational Site, Ōita

060-0001

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

062 0007

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

329 0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi

424 0853

Novo Nordisk Investigational Site, Shizuoka

985 0852

Novo Nordisk Investigational Site, Tagajō-shi

569 1096

Novo Nordisk Investigational Site, Takatsuki-shi, Osaka

329 0498

Novo Nordisk Investigational Site, Tochigi

104 0044

Novo Nordisk Investigational Site, Tokyo

113 0031

Novo Nordisk Investigational Site, Tokyo

125 0054

Novo Nordisk Investigational Site, Tokyo

755 0067

Novo Nordisk Investigational Site, Yamaguchi

235 0045

Novo Nordisk Investigational Site, Yokohama